|
Infection |
IV treatment |
Oral treatment |
Total duration |
|
Severe
gastroenteritis requiring hospital admission cause |
Do not use until established
diagnosis or patient seriously ill |
Ciprofloxacin 500mg bd |
3 to 5 days |
|
Invasive Salmonellosis |
Ciprofloxacin 200 - 400mg bd* |
Ciprofloxacin 250 - 500mg bd |
14 days |
|
Enteric Fever (Typhoid) |
Ciprofloxacin 200 - 400mg bd* |
Ciprofloxacin 250 - 500mg bd |
14 days |
|
Severe Campylobacter Enteritis |
Clarithromycin 500mg bd |
3-5 days |
|
|
Bacillary |
Antibiotic not usually recommended
in Shigella
sonnei infections |
||
|
Biliary Tract Infection (cholecystitis / cholangitis)
|
Tazocin 4.5g tds* plus gentamicin |
Ciprofloxacin 500mg bd
|
7-10 days |
|
Infective pancreatitis |
Tazocin 4.5g tds* plus gentamicin
(if severe / no improvement) N.B. prolonged IV therapy may be necessary due to compromised oral absorption. |
Ciprofloxacin 500mg bd
|
7-10 days |
|
Peritonitis |
Cefuroxime
750mg-1.5g tds* plus metronidazole 500mg tds plus / minus gentamicin |
Ciprofloxacin 500mg bd
|
Once clinical improvement occurs oral antibiotics can be used for a further 7-10 days. |
|
Diverticulitis |
Cefuroxime 750mg - 1.5g TDS* plus metronidazole 500mg TDS |
Co-amoxiclav 625mg TDS |
IV treatment until clinical improvement usually up to 4 days then oral therapy for 7-10 days |
|
Antibiotic Associated Colitis |
If oral route not available metronidazole 500mg tds |
Metronidazole
400mg tds |
10 days |
+N.B. Please be aware of other
causes of diarrhoea such as Clostridium
difficile (especially if
recent antibiotic exposure - refer to section 26), E.coli
0157 or Norwalk virus
* For
patients with renal impairment refer to section 23 for dosage adjustments
|
Condition |
Treatment |
Duration |
|
Helicobacter eradication |
First line use : |
7 days |
|
Helicobacter eradication Penicillin- |
Omeprazole 20mg bd orally plus metronidazole 400mg bd and clarithromycin 500mg bd orally |
7 days |
Sensitivity testing has confirmed
that the local area has a high prevalence of metronidazole-resistant Helicobacter.
The importance of completing the
course should be emphasised to the patient - this treatment may
transform subsequent management of the ulcer by preventing relapse
and eliminating the need for long-term treatment. Information
regarding side-effects should also be given.
N.B.
Dual regimens are not now recommended, as eradication rates are much lower.
Consult a gastroenterologist if the
latest information or clinical advice is required.